Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

54 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of Human monocyte derived macrophages exposed to arachidonic acid, IL6 or both

ABSTRACT: Monocyte derived macrophages were exposed to arachidonic acid, IL6 or both.

INSTRUMENT(S): NextSeq 550

ORGANISM(S): Homo sapiens

SUBMITTER: Florian Finkernagel

PROVIDER: E-MTAB-10868 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq of monocyte derived macrophages exposed to arachidonic acid, interferon beta, or interferon gamma

Project description:Monocyte derived macrophages were exposed to arachidonic acid, interferon beta, or interferon gamma

2021-12-31 | E-MTAB-10867 | biostudies-arrayexpress

MDMs Solvent, AA, IL6, AA+IL6

Project description:Monocyte derived macrophages were exposed do arachidonic acid, IL6 or both.

2020-12-10 | E-MTAB-8830 | biostudies-arrayexpress

Macrophages Solvent, AA, LPS, AA+LPS

Project description:Monocyte derived macrophages were exposed to arachidonic acid, LPS or both

2021-12-31 | E-MTAB-10866 | biostudies-arrayexpress

Effect of genetic DRYK1B KO

Project description:DYRK1B was deleted in a murine PDAC cell line (mKPc4) and assayed for genotype specific changes in gene expression.

2024-05-29 | E-MTAB-13666 | biostudies-arrayexpress

Mouse bone-marrow-derived macrophages treated with supernatant of DYRK1B-deletion / Wildtype mKpc4 cells

Project description:Mus musculus macrophages were derived from bone marrow, and treated with the supernatant of of DYRK1B-deletion (multiple clones) or Wildtype mKpc4 cells.

2024-05-29 | E-MTAB-13668 | biostudies-arrayexpress

RNAseq of mutant TP53 HCT116 cell line clones generated via CRISPR editing

Project description:To compare the impact of several TP53 mutant variants in an isogenic setting, different TP53 mutations were introduced in HCT116 colorectal carcinoma cells. This parental cell line is wild-type for TP53 and shows a prototypical p53 response. To ensure unambigous genotype-phenotype correlations, the cell were haploidized prior to CRISPR-editing by introducing inactivating deletions of intronic splicing into one of the two TP53 alleles, leaving only one functional copy of TP53. The remaining TP53 allele was altered by inserting a LoxP-flanked transcriptional stop cassette (Lox-Stop-Lox, LSL) into intron 4, which allowed reversible silencing of TP53 expression. The LSL cassette was then specifically targeted with CRISPR/Cas9 to introduce a variety of different mutant p53 alleles. The competency of the mutated p53 allele to induce a p53 response upon activation using Nutlin-3a was then assessed in an RNAseq experiment.

2024-10-16 | E-MTAB-12734 | biostudies-arrayexpress

Riboseq and Quantseq of neuroblastoma cell line SH-SY5Y expressing MAPT-AS1 constructs

Project description:The aim of this experiment was to assess the on- and off-target effects of MAPT-AS1 expression, and whether mutations/deletions to MAPT-AS1 alter these effects. SHSY5Y cells stably expressing variants of MAPT-AS1 were analyzed by Riboseq and Quantseq.

2021-03-20 | E-MTAB-9921 | biostudies-arrayexpress

RNA seq of HEK293 treated with Blebbistatin or expressing C9orf72 associated Di Peptide Repeats (DPRs)

Project description:To identify if the alteration of Myosin activity identified in DPRs expressing cells induced alterations in the transcriptome profile of cells. For that purpose, we compared the changes in HEK293 cells transcriptome induced by a known myosin activity disruptor, Blebbistatin, with DPRs expressing cells .

2023-10-09 | E-MTAB-13292 | biostudies-arrayexpress

RNA-seq of differentiated organoids from a patient with an AGR2 mutation, patients with ulcerative colitis, and non-IBD controls, treated with vehicle control or tunicamycin

Project description:RNA-seq of differentiated organoids (day 7) from a patient with an AGR2 mutation, patients with ulcerative colitis, or non-IBD controls. After 6 days differentiation, organoids were treated for 24 hours with Tunicamycin (T7765, Sigma Aldrich,1 µg/ml) or vehicle control (0.1 % DMSO).

2023-04-30 | E-MTAB-12309 | biostudies-arrayexpress

LPA treatment of Ocmi_91s ovarian carcinoma cells.

Project description:Effect of LPA-Mixture (16:0, 18:0 18:1 18:2, 20:4) and LPAR2 specific (H2L5186303) or LPAR1 specific (Ro6842262) Inh. in OC91s cells.

2023-05-01 | E-MTAB-12487 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data